Administration of rituximab during the first trimester of pregnancy without consequences for the newborn

E-viri

PDF

Celotno besedilo

Recenzirano Odprti dostop

Administration of rituximab during the first trimester of pregnancy without consequences for the newborn

Ojeda-Uribe, M; Gilliot, C; Jung, G; Drenou, B; Brunot, A

Journal of Perinatology, 04/2006, Letnik: 26, Številka: 4

Journal Article

Rituximab, a chimeric mouse/human monoclonal antibody that binds to the CD20 antigen, is part of current treatment of many B-cell malignancies and several autoimmune diseases. Very few cases of rituximab administration during pregnancy have been described. We report here the case of rituximab administration during the first trimester of pregnancy in a woman with autoimmune hemolytic anemia. No significant effects were observed in B-cell counts or the immune status of the newborn.

Išči dalje

Avtor

Ojeda-Uribe, M | Gilliot, C | Jung, G | Drenou, B | Brunot, A

Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.

Leto	Faktor vpliva		Izdaja		Kategorija		Razvrstitev
Leto	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Povezave do osebnih bibliografij avtorjev	Povezave do podatkov o raziskovalcih v sistemu SICRIS

Vir: Osebne bibliografije in: SICRIS

Naloži sliko

Vnos na polico

Dodajanje gradiva na polico je uspelo.

Dodajanje gradiva na polico je spodletelo.

Dodajanje gradiva na polico ni bilo potrebno.

Trajna povezava

E-pošta

Faktor vpliva

Izberite knjižnično izkaznico:

Baze podatkov, v katerih je revija indeksirana

Citiranje

Tema